Moreover, inhibiting RANKL has been shown to improve the effectiveness of immune-checkpoint inhibitors (ICI) targeting CTLA-4 or PD(L)-1 in preclinical models of cancer [8,9]. This evidence concerns the gene TNFSF11 and cancer.